Acsis, Inc. Appoints Paul Allen to Board of Directors
News Jan 27, 2012
The software solutions provider of products and services for supply chain optimization, serialization, visibility and traceability, announced the appointment of Paul Allen as a new member of its Board of Directors.
"Paul provides a unique combination of science and business acumen, along with exceptional leadership," said Neil Thall, Acsis CEO/President and fellow board member. "His career successes exemplify the goals we have for providing industry-leading solutions, especially in his areas of expertise."
As vice president of strategic services at Olson Research Group, Allen is responsible for developing new services designed specifically for the pharmaceutical, biotechnology, and medical devices industries. He is also charged with leading an external team of experienced partners and consultants who specialize in delivering solutions to these industries.
Allen was the former President of Genactis, Inc., a firm that specialized in research-based consulting and focused on early stage product development engagements across the life sciences business sector. Allen spent nine years at Clarkston Consulting where he was the managing partner for their global life sciences practice. He spent four years at IMS Health, where he served as vice president of marketing, and was responsible for more than 60 marketing and sales professionals. Prior to IMS Health, Paul was responsible for managing the sales and operations, market research, and business development for Novo Nordisk Pharmaceuticals.
Allen has moderated numerous industry conferences focused on issues within the pharmaceutical industry, from preparing for FDA inspections to developing a "risk management approach" to quality systems strategies. In addition, Allen has experience in regulatory compliance (both for commercial operations and manufacturing areas), business process redesign, government pricing and contracting strategies and systems, and business intelligence systems.
Allen has been a featured speaker at national and international pharmaceutical conferences where he covered topics from FDA regulatory compliance, to e-marketing and direct-to-consumer strategies, to supply chain optimization in Life Sciences and sales force productivity through innovative compensation methods.
Allen received an M.B.A. from Rutgers University in New Brunswick, New Jersey, with a concentration in marketing sciences, completed Graduate Course work at the Medical College of Pennsylvania in Philadelphia, Pennsylvania, and a B.S. in biology and chemistry from Eastern University in St. David's Pennsylvania.
"I am excited to be joining a company that has pioneered cutting-edge tracking software to some of the world's most prestigious manufacturers," Allen said. "It's an honor to be part of the Acsis, Inc. team and I look forward to contributing to the next phase of the company's growth."
Scientists working in a range of disciplines joined forces to identify a new approach to combat African sleeping sickness. Their research revealed a promising strategy to develop a suitable agent. This novel concept could also be employed in the future rational design of drugs for the treatment of other diseases.READ MORE
Researchers warn that--as the predictive power of genes tied to learning and educational outcomes increases and access to genetic data expands--researchers, educators, and policymakers must be cautious in how they use such data, interpret related findings, and, in the not-too-distant future, apply genetics-informed student interventions.READ MORE
Scientists at Tokyo Tech, Ricoh co. and The National Institute of Advanced Industrial Science and Technology have developed an ultra-low-power atomic clock (ULPAC) for small satellites to enable future communication systems beyond 5G. The proposed device outperforms the current industry standards in various benchmarks, such as size, stability, and power consumption.